Joana Serra Caetano

Joana Serra Caetano

Auto-generated profile, based on publicly available information

Joana Serra Caetano

Hosp Pediatr Coimbra, Unidade Local Saude Coimbra, Unidade Endocrinol Pediat Diabet & Crescimento, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2024 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
FPFrancisca Puga
Francisca Puga
LCLaura Correia
Laura Correia
Inês VieiraInês Vieira
Inês Vieira
JCJoana Serra Caetano
Joana Serra Caetano
RCRita Cardoso
Rita Cardoso
AMAlice Mirante
Alice Mirante
Objective: Differentiated thyroid cancer (DTC) is the most common pediatric endocrine cancer but studies are scarce. Latest recommendations advocate for an individualized risk-based approach to select patients for additional therapy. Lymphovascular invasion is not considered, despite being a well-known risk factor in the adult population. The aim of this study was to describe the outcomes of a cohort of DTC patients diagnosed at pediatric age and to evaluate the impact of lymphovascular invasion on the risk of persistence/ recurrence. Methods: A retrospective study of patients diagnosed with DTC at pediatric age from 2010 to 2022 at a single center was performed. All patients had total thyroidectomy. Radioactive iodine therapy (RAI) was used in selected patients. The response to therapy and occurrence of persistent/recurrent disease were evaluated. Results: A total of 21 DTC were diagnosed, mostly papillary thyroid carcinoma (PTC) (81.0%, n=17). Six patients (28.6%) had nodal involvement and one (4.8%) had lung metastasis at the time of the diagnosis. Lymphovascular invasion was present in 11 patients (52.4%). After surgery, 13 patients (61.9%) underwent RAI. The mean follow-up time was 5.7 +/- 3.1 years. In total, 6 patients (31.6%) experienced persistent/recurrent disease during the follow-up time. Among PTC patients, persistent/recurrent disease was more frequent in the presence of lymphovascular invasion [55.6% (5/9) vs. 0.0% (0/6), p=0.031]. Conclusion: An individualized risk-based approach is recommended. Our study suggests that lymphovascular invasion may be associated with a higher risk of persistence/recurrence and should therefore be considered for decision making in children and adolescents with PTC.

25 August 2022 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
NBNádia Mourinho Bala
Nádia Mourinho Bala
RGRaquel S. Gonçalves
Raquel S. Gonçalves
JCJoana Serra Caetano
Joana Serra Caetano
RCRita Cardoso
Rita Cardoso
IDIsabel Dinis
Isabel Dinis
AMAlice Mirante
Alice Mirante
Objective: Primary adrenal insufficiency (PAI) is a rare condition in children, and is potentially life-threatening. The most common cause is congenital adrenal hyperplasia, and autoimmune etiology is the most frequent acquired cause in this age group. Symptoms are usually non-specific and, when suspected, investigation should include adrenocorticotropin hormone (ACTH) and morning serum cortisol measurement and, in some cases, a cosyntropin test to confirm the diagnosis. Prompt treatment is essential to prevent an adverse outcome. Methods: We retrospectively collected clinical and laboratory data from adrenal insufficiency due to autoimmune adrenalitis, observed from 2015 to 2020 in a pediatric endocrinology department of a tertiary care hospital. Results: Eight patients were identified, seven males and one female, with age at diagnosis between 14 and 17 years. The symptoms at presentation ranged from non-specific symptoms, such as chronic fatigue and weight loss, to a severe presentation, with altered mental status and seizures. The median duration of symptoms was 4.5 months. The diagnosis was confirmed by serum cortisol and plasma ACTH measurement and all were confirmed to have autoimmune etiology (positive anti-adrenal antibodies). At diagnosis, the most common laboratory abnormality was hyponatremia. All patients were treated with hydrocortisone and fludrocortisone. One patient presented with evidence of type 2 autoimmune polyglandular syndrome. Conclusion: PAI is a rare condition in the pediatric age group. Due to non-specific symptoms, a high index of suspicion is necessary to establish a prompt diagnosis. Once an autoimmune etiology is confirmed, it is important to initiate the appropriate treatment and search for signs and symptoms of other autoimmune diseases during follow-up.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
DSDiana Festas da Silva
Diana Festas da Silva
ALAdriana De Sousa Lages
Adriana De Sousa Lages
JCJoana Serra Caetano
Joana Serra Caetano
RCRita Cardoso
Rita Cardoso
IDIsabel Dinis
Isabel Dinis
AMAlice Mirante
Alice Mirante
Introduction: Hypoparathyroidism is characterized by low or inappropriately normal PTH production, hypocalcemia and hyperphosphatemia. Autosomal dominant hypocalcemia (ADH) type 1 is one of the genetic etiologies of this, caused by heterozygous activating mutations in the CASR gene. Some individuals fail to meet treatment goals despite standard therapy. Clinical Case: A 13-year-old male patient was admitted in the emergency department due to syncope during physical activity. There was no reference to seizures or other complaints. Standard screening for metabolic diseases revealed no changes at the 7th day of life and family history was unremarkable. There was a history of febrile seizures up to 5 years of age with several hospitalizations for diagnosis investigation that were inconclusive. Physical examination showed a positive Chvostek signal, without other changes. A basic workup revealed hypocalcemia 1.67mmol/L (NR: 2.19-2.66), hyperphosphatemia 3.06mmol/L (NR: 0.95-1.75), hypomagnesemia 0.62mmol/L (NR: 0.7-1.0), low 25Hydroxyvitamin D 8.7ng/mL (NR: >30ng/mL) and inappropriately low PTH 4.0pg/mL (NR: 16.0-87.0). Cranial computed tomography scan showed bilateral calcifications of the basal ganglia. Dual-energy x-ray absorptiometry revealed bone mineral density z-scores increased 15% in spine lumbar and decreased 7% in left femur. Cardiac ultrasound and electrocardiography were normal. The patient started therapy with intravenous calcium gluconate. During this treatment, he developed significant calcification of the peripheral veins at the site of administration, leading to intravenous therapy suspension. The dose of oral calcium, calcitriol and magnesium was gradually increased and sevelamer started to control hyperphosphatemia. Despite the optimization, the patient maintained hypocalcemia refractory to standard therapy. As a last resource strategy in therapeutic optimization, the patient started on rhPTH (1-34). Ever since, the patient has been clinically asymptomatic with biochemical stability and with a reasonable quality of life. At age 18, renal ultrasound revealed diffuse medullary nephrocalcinosis. The genetic testing revealed a novel variant c.368T>C p.(Leu123Ser) likely pathogenic in heterozygosity in the CASR gene, suggesting the diagnosis of ADH type 1. The patient′s mother did not give her consent for genetic study and patient’s father had already died with a diagnosis of acute leukemia. Conclusion: This case can be explained by the presence of a likely pathogenic variant in heterozygosity in the CASR gene that has been described in the medical literature that has not been identified in gnomAD population database, suggesting the diagnosis of ADH type 1. rhPTH (1-34) may be a treatment option for those individuals who are not well controlled on standard therapy, but long-term follow-up studies are needed to reinforce its safety.

1 January 2020 in Revista Paulista de Pediatria
Verified
Journal Article
Open access
PDF file
PMPatrícia Sofia Ferreira Miranda
Patrícia Sofia Ferreira Miranda
EPEster Preciosa Maio Nunes Pereira
Ester Preciosa Maio Nunes Pereira
JBJoana Serra Caetano Baltazar Barreto
Joana Serra Caetano Baltazar Barreto
MHMargarida Maria Videira Henriques
Margarida Maria Videira Henriques
MMMaria Alice Santos Cordeiro Mirante
Maria Alice Santos Cordeiro Mirante
LRLina Maria Jesus Ferreira Cardoso Ramos
Lina Maria Jesus Ferreira Cardoso Ramos
Objective: To present a case of bilateral gynecomastia in a prepubertal boy with autism spectrum disorder, diagnosed with myotonic dystrophy type 1. Case description: A 12-year-old boy with autism spectrum disorder presented at a follow-up visit with bilateral breast growth. There was a family history of gynecomastia, cataracts at a young age, puberty delay, and myotonic dystrophy type 1. The physical examination showed that he had bilateral gynecomastia with external genitalia Tanner stage 1. Neurologic examination was regular, without demonstrable myotonia. The analytical study revealed increased estradiol levels and estradiol/testosterone ratio. After excluding endocrine diseases, the molecular study of the dystrophia myotonica protein kinase gene confirmed the diagnosis of myotonic dystrophy type 1. Comments: A diagnosis of prepubertal gynecomastia should include an investigation for possible underlying diseases. This case report highlights the importance of considering the diagnosis of myotonic dystrophy type 1 in the presence of endocrine and neurodevelopmental manifestations.

8 November 2021 in Endocrine Abstracts
Verified
Journal Article
Closed access
IRInes Rosinha
Ines Rosinha
RCRita Cardoso
Rita Cardoso
IDIsabel Dinis
Isabel Dinis
AMAlice Mirante
Alice Mirante
JSJoana Serra-Caetano
Joana Serra-Caetano
Background: Childhood cancer survivors (CCS) are at high risk of 25-hydroxivitamin D (25(OH)D) inadequacy and the lack of a consensual definition has hampered its epidemiological study. Despite international recommendations, bone health and vitamin D inadequacy (VDI) are still quite undervalued, even in a high-risk population as CCS, due to disease treatment, physical limitations and insufficient solar exposure. Objectives: Our aims were to determine the prevalence of plasma 25(OH)D inadequacy in CCS in a tertiary pediatric center and to identify potential risk and protective factors for VDI. Material and Methods: A retrospective cross-sectional cohort study was performed in Portuguese survivors under the age of eighteen diagnosed, followed and treated for cancer from January 1, 2016 to April 30, 2021. 25(OH)D status was defined according to Munns et al Global Consensus: deficiency (<12 ng/mL) and insufficiency (12-20 ng/mL). Bivariate analysis was carried out to study the impact of age at diagnosis, pubertal stage, cancer type and treatment exposures. Results: Of the 219 CCS recruited, 94 (43%) had at least one routine 25(OH)D blood screening, with median age 7.71 years, interquartile range: 10; 55% males. Of these, 25(OH)D inadequacy was highly prevalent (58.5%) among cancer survivors: 8 (14.5%) deficiency and 47 (85,5%) insufficiency; only 39 (70.9%) of them underwent supplementation. Median of 25(OH)D levels was 17.0 ng/mL (IQR: 7.0; minimum: 4.0). The most frequent oncologic diagnoses included lymphoproliferative disorders (39%), brain tumors (41%; 13% gliomas), solid non-brain tumors (15%) and Langerhans cell histiocytosis (4%). Thirty percent of survivors had at least one sequel, being hemiparesis (5%) the most prevalent one; 13% had metastatic disease. There was a positive and statistically significant correlation between plasma 25(OH)D level and age at diagnosis (P < 0,001; δ: 0.484). Concerning pubertal stage, cancer type and treatment exposures, no statistically significant associations were found. Conclusion: The prevalence of 25(OH)D inadequacy was even higher than expected in this population, considering international literature and country latitude. This reinforces the necessity to value bone health by diagnosing VDI, ensuring therapeutic supplementation and monitoring in risky populations.